Dallas, TX - December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D.,…
https://etira.life/wp-content/uploads/2024/12/image.png566658Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-12-02 10:06:322024-12-03 11:33:29Dr. Raj appointed as Etira Chief Medical Officer
Sydney, Australia - November 18, 2024: We are excited to announce that the first patient in our ERX-315-101 Phase 1 clinical trial has successfully received their first doses of ERX-315 at The Kinghorn Cancer Center (TKCC) in Sydney, Australia.…
Dallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath,…
Seattle, WA - September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th…
https://etira.life/wp-content/uploads/2024/09/Unknown.jpeg8191276Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-09-23 10:22:362024-09-24 11:49:29Validation of ERX-208 in Ovarian Cancer
Sydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney…
https://etira.life/wp-content/uploads/2024/09/image.png15682324Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-09-04 10:06:482024-10-15 12:30:25ERX-315-001 SITE INITIATION VISIT @TKCC
Dallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled "A Phase…
https://etira.life/wp-content/uploads/2024/08/shutterstock_700277188_edited.jpeg690812Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-08-01 11:49:472024-10-15 12:30:01ERX-315 CLINICAL TRIAL APPROVED BY HREC
Melbourne, Australia - July 10, 2024: The expansion of Etira partner Medicines Manufacturing Innovation Centre (MMIC) to the Monash Technology Precinct in Clayton was highlighted in the press. This expansion will enable further opportunities…
https://etira.life/wp-content/uploads/2024/07/shutterstock_125779055-scaled.jpg25602127Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-07-10 12:16:072024-08-12 13:36:07Etira’s Australian partner MMIC expands
Dallas, TX – June 15, 2024: The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions. Herein,…
https://etira.life/wp-content/uploads/2024/06/image.jpeg12641756Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-06-20 10:43:312024-08-02 11:54:06DECRYPTING THE OLIGO-BENZAMIDE PLATFORM
Dallas, TX – May 14th, 2024: Etira is pleased to announce the submission of the regulatory documents for approval of administration of its breakthrough oncology drug ERX-315 to the Human Research Ethics Committee (HREC) in Australia. This…
https://etira.life/wp-content/uploads/2024/05/Etira-Image-for-Press-Release.jpg5631000Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-05-15 12:36:582024-09-20 11:13:35ERX-315 SUBMITTED FOR HREC APPROVAL
San Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity…
https://etira.life/wp-content/uploads/2024/05/Unknown-scaled.jpeg19202560Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-04-10 11:35:082024-05-17 11:42:20ERX-208 potency in Ovarian Cancer
Dr. Raj appointed as Etira Chief Medical Officer
NewsFirst patient dosed in ERX-315-101 Clinical Trial
NewsDrs. Jenkins and Stebbing join Etira Board
NewsValidation of ERX-208 in Ovarian Cancer
NewsERX-315-001 SITE INITIATION VISIT @TKCC
NewsERX-315 CLINICAL TRIAL APPROVED BY HREC
NewsEtira’s Australian partner MMIC expands
NewsDECRYPTING THE OLIGO-BENZAMIDE PLATFORM
NewsERX-315 SUBMITTED FOR HREC APPROVAL
NewsERX-208 potency in Ovarian Cancer
News